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Abstract
Background: Guidelines from the Infectious Diseases Society of America/The American Thoracic Society (IDSA/ATS)
provide recommendations for diagnosis and treatment of ventilator-associated pneumonia (VAP). However, the
mere presence of guidelines is rarely sufficient to promote widespread adoption and uptake. Using the Systems
Engineering Initiative for Patient Safety (SEIPS) model framework, we undertook a study to understand barriers and
facilitators to the adoption of the IDSA/ATS guidelines.
Methods: We conducted surveys and focus group discussions of different health care providers involved in the
management of VAP. The setting was medical-surgical ICUs at a tertiary academic hospital and a large
multispecialty rural hospital in Wisconsin, USA.
Results: Overall, we found that 55 % of participants indicated that they were aware of the IDSA/ATS guideline. The
top ranked barriers to VAP management included: 1) having multiple physician groups managing VAP, 2) variation
in VAP management by differing ICU services, 3) physicians and level of training, and 4) renal failure complicating
doses of antibiotics.
Facilitators to VAP management included presence of multidisciplinary rounds that include nurses, pharmacist and
respiratory therapists, and awareness of the IDSA/ATS guideline. This awareness was associated with receiving
effective training on management of VAP, keeping up to date on nosocomial infection literature, and belief that
performing a bronchoscopy to diagnose VAP would help with expeditious diagnosis of VAP.
Conclusions: Findings from our study complement existing studies by identifying perceptions of the many
different types of healthcare workers in ICU settings. These findings have implications for antibiotic stewardship
teams, clinicians, and organizational leaders.
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Background
Ventilator-associated pneumonia (VAP) is the most
common nosocomial infection in the intensive care
unit (ICU), with an incidence ranging from 9 % to as
high as 39 % [1–4]. VAP is associated with prolonged
hospitalization, health care costs and high mortality
rates [5–7]. Healthcare-associated pneumonia, the ma-
jority of which in the ICU is VAP, accounts for more
than 50 % of the antibiotics prescribed in the ICU and
a significant proportion of inappropriate and overpre-
scribed antibiotics [8, 9]. Several studies have shown
that inappropriate treatment of VAP leads to adverse
outcomes [10, 11].
Guidelines from the Infectious Diseases Society of
America/The American Thoracic Society (IDSA/ATS)
provide recommendations for diagnosis and treatment
of VAP [12]. However, it has become clear that the
mere presence of a guideline, while necessary, is rarely
sufficient to promote widespread adoption and uptake
[13–23]. It is unclear as to what extent these guidelines
are currently followed in ICUs and what barriers may
exist that impede the implementation of these guidelines.
A growing body of literature has identified barriers that
must be addressed for guidelines to be effectively incor-
porated into clinical practice [24, 25]. We used a novel
systems engineering framework (Systems Engineering
Initiative for Patient Safety-SEIPS) to develop and ad-
minister a survey to understand barriers and facilitators
to the adoption of the IDSA/ATS guideline.
These barriers may be broadly categorized into the five
elements of the work system component of the SEIPS
model [26]: 1) characteristics of the guideline to be in-
troduced (the ‘tool/technology’ element of the work sys-
tem model), 2) characteristics of the individuals who
play a role in adoption and usage of the guideline (the
‘individual’ element), 3) use of the guideline for changing
behavior (the ‘task’ element), 4) characteristics of the
organization in which the change is to occur, such as ex-
tent of training (the ‘organization’ element), and 5) char-
acteristics of the physical environment in which the
change is to occur (the ‘environment’ element) [27]. The
objective of this study was to characterize the barriers




This study was conducted in medical-surgical ICUs at
the University of Wisconsin Hospital, a tertiary academic
hospital (hospital A) and St. Joseph’s Hospital, a large
multispecialty rural hospital (hospital B) in the Midwest-
ern US. The medical-surgical ICU at the University of
Wisconsin is a 24 bed ICU staffed by board certified
intensivists and anesthesiologists. The medical-surgical
ICU at St Joseph’s hospital is also staffed by trained
intensivists. The study was conducted in 2008–2009.
Data collection
Focus group methods and development of survey
To identify barriers and facilitators of managing VAP in
ICUs from the providers’ perspective, a survey was de-
veloped based on literature review and content analysis
of data collected from focus groups. Two focus group
discussions (FGDs) (one with physicians and one with
nurses, respiratory therapists and pharmacists) were
conducted at each of the two hospitals. The objective of
the FGDs was to identify and discuss issues of VAP man-
agement using the SEIPS framework (Fig. 1). Content ana-
lysis of focus groups’ transcripts identified a total of 193
“unique” comments, which were further classified into 9
themes: (1) communication between providers, (2) diffi-
culty in diagnosing VAP, (3) education related to VAP and
Fig. 1 Adaptation of the SEIPS model to the Management of Ventilator-Associated Pneumonia in Intensive Care Units. The five interacting
components of the work system part of the SEIPS model are shown, the process involved and the resulting outcomes
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VAP management, (4) guideline awareness and use, (5)
management of the condition, (6) provider responsibilities,
(7) technology and its use, (8) use of clinically indicated
tests, and (9) variation in practice. Based on the comments
and themes identified, a survey was developed and pilot
tested on four participants, all of whom were involved
in medical management of VAP. They included one
physician, one nurse, one respiratory therapist and one
pharmacist. Revisions to the content of the questions
were made to the survey according to the feedback
from pilot testing.
The final survey was adapted to the two hospitals.
The version developed for hospital A consisted of five
sections. Background had two questions asking the par-
ticipants if they were aware of the IDSA/ATS guideline
for VAP management and to what extent they were
willing to follow the guideline. Methods asked participants
to indicate to what extent they agree or disagree with 45
statements on VAP management, using a 5-point Likert
scale (1 strongly agree, 2 agree, 3 neither agree nor dis-
agree, 4 disagree and 5 strongly disagree). Results asked
participants to indicate the frequency with which 17 situa-
tions occurred in VAP management. This used a 5-point
Likert scale (1 rarely, 2 occasionally, 3 sometimes, 4 fairly
often and 5 very often). Discussion had five yes/no ques-
tions. These addressed VAP management and diagnosis
guidelines and assessed considerations regarding the mini-
bronchoalveolar lavage (mini-BAL) procedure. Conclusion
collected demographic information of participants includ-
ing gender, age, job position, work shift, and average
length working for the present employer in the current
position.
The survey developed for hospital B similarly had five
sections, but a few questions were different from those
for hospital A. This was because, in addition to the
IDSA/ATS guideline for management of VAP, hospital A
also has its own VAP management guidelines that were
largely similar to national guidelines but not identical.
Procedure
The paper survey was distributed to all physicians,
nurses, respiratory therapists and pharmacists who prac-
ticed in the medical-surgical ICUs at both hospitals. The
study was approved by the University of Wisconsin-
Madison and the Marshfield Clinic Institutional Review
Boards (IRBs). We obtained informed consent from all
participants involved in the study.
Analysis
Survey data was entered (with verification for accuracy)
in an SPSS database. Descriptive statistics were calculated
to identify top-ranked barriers and facilitators of VAP
management. For each question, the number and per-
centage of participants who chose each of the available
response categories were calculated. If the wording of a
question was positive (e.g., pharmacist participation on
ICU rounds is beneficial), then participants who chose
“agree” and “strongly agree” or “fairly often” and “very
often,” (when the question was about frequency), con-
sidered it as a facilitator; and participants who chose
“disagree” and “strongly disagree” or “occasionally” and
“rarely” considered it as a barrier. In contrast, if a ques-
tion was stated in a negative manner (e.g., having mul-
tiple groups of physicians manage patients in the ICU
complicates VAP guideline use), then participants who
chose “agree” and “strongly agree” or “fairly often” and
“very often” considered it as a barrier; and participants
who chose “disagree” and “strongly disagree” or “occasion-
ally” and “rarely” considered it as a facilitator. Questions
were ranked according to the percentage of respondents
who considered them as barriers or as facilitators.
Statistical analysis was performed to compare percep-
tions of participants from different professional groups
and to examine the impact of guideline awareness on
the perceptions of participants. Three questions designed
only for hospital A were excluded from the analysis be-
cause they were not applicable to hospital B and 7 ques-
tions were excluded from the analysis because they were
designed only for physicians and were not applicable to
the other healthcare professional groups. Analysis for the
remaining questions proceeded as follows. We treated
questions that used a 5-point Likert scale (1 rarely, 2 occa-
sionally, 3 sometimes, 4 fairly often and 5 very often) or (1
strongly agree, 2 agree, 3 neither agree nor disagree, 4 dis-
agree and 5 strongly disagree), depending on whether the
question was about agreement or frequency, as continuous
variables [28]. Because the dependent variables examining
the differences between physicians, nurses, respiratory
therapists and pharmacists were not normally distributed,
we conducted one-way non-parametric ANOVA. When
significant differences were identified between different
professional groups, post-hoc analysis was performed
using the Mann-Whitney test. This test was also used to
examine differences between participants who were aware
of and who were not aware of the IDSA/ATS guideline for
VAP management. The Mann-Whitney test works by
ranking all the values from low to high. Therefore, the hy-
pothesis tested in these tests was that means of the ranks
in the two comparison groups was zero.
Results
Surveys were distributed to 115 participants from hos-
pital A and 85 participants in hospital B. A total of 150
participants completed the survey, among whom 87
were from hospital A and 63 participants were from hos-
pital B. The overall response rate was 75 %. (hospital A:
75 %, hospital B: 74 %). Table 1 shows the demographics
of the participants from the two hospitals.
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Barriers and facilitators
The top ranked barriers to VAP management identified
in this study included (Table 2): 1) having multiple
physician groups managing VAP, 2) variation in VAP
management by differing ICU services, 3) physicians
and level of training, and 4) renal failure complicating
doses of antibiotics.
Facilitators to VAP management (Table 3) included
presence of multidisciplinary rounds that include nurses,
pharmacist and respiratory therapists, and awareness of
the IDSA/ATS guideline. This awareness was associated
with receiving effective training on management of VAP,
keeping up to date on nosocomial infection literature,
and belief that performing a bronchoscopy to diagnose
VAP would help with expeditious diagnosis of VAP.
Table 4 shows the number of participants from each
professional group who were aware of and who were not
aware of the IDSA/ATS guideline for VAP management.
Overall, 55 % of participants indicated that they were
aware of the IDSA/ATS guideline for VAP management.
The next set of analyses shows results of the one-way
non-parametric ANOVA and Mann-Whitney tests ap-
plied to items classified within each of nine themes
identified from the content analysis of focus groups.
The category with a smaller mean rank for a positively
worded questions indicates that the group did better on
that item than the comparison group, while a smaller
mean rank on a negatively worded question indicates
that the group did worse than the comparison.
None of the questions classified under three of the
nine themes—variation in practice, communication
between providers, and technology and its use differed
significantly between participants who were aware of
the guideline and those who were not (results not pre-
sented). For professional groups, only statistically sig-
nificant (Bonferroni corrected) pairwise comparisons
are presented in the paper and are summarized in
Table 5 (Online supplemental material).
Compared to other professional groups, a higher pro-
portion (71 %) of respiratory therapists agreed that more
clinically useful specimens are collected when mini-BALs
are performed (followed by physicians (61 %), nurses
(45 %) and then pharmacists (25 %), (p = 0.01).
Discussion
VAP accounts for a major proportion of anti-infective
use in the ICU. Recent data indicate that antibiotic use
is significantly higher in ICU patients compared with
non-ICU patients for most antimicrobials [29] Optimiz-
ing management of VAP is clearly essential yet remains
variable [30, 31] and is associated with suboptimal pre-
scribing practices [32].






Male 18 (21 %) 20 (32 %)
Female 66 (76 %) 42 (67 %)
Missing 3 (3 %) 1 (2 %)
Agea
Less than 25 5 (6 %) 2 (3 %)
Between 25 and 34 41 (47 %) 23 (37 %)
Between 35 and 44 19 (22 %) 14 (22 %)
Between 45 and 54 16 (18 %) 17 (27 %)
More than 55 3 (3 %) 6 (10 %)
Missing 3 (3 %) 1 (2 %)
Job positiona
Nurses 30 (35 %) 27 (43 %)
Pharmacists 22 (25 %) 4 (6 %)
Respiratory therapists 34 (39 %) 15 (24 %)
Physicians 1 (1 %) 17 (27 %)
Work shift b
7 am – 7 pm 40 (46 %) 36 (57 %)
7 pm – 7 am 18 (21 %) 15 (24 %)
7 am – 3 pm 19 (22 %) 13 (21 %)
3 pm – 11 pm 8 (9 %) 10 (16 %)
11 pm – 7 am 7 (8 %) 5 (8 %)
Average length working for the present
employer
10.5 years 9.2 years
Average length working in the current position 8.8 years 8.8 years
aTotal percentage does not sum to 100 % because of rounding
bTotal percentage exceeds 100 % because more than one option could
be chosen
Table 2 List of the top-ranked barriers to VAP management
Barriers Percent Response category
Having multiple physician groups manage patients in the ICU complicates VAP guideline use. 67.3 % Agree & strongly agree
There is variation in VAP management depending on what service the ICU patient is on. 64.3 % Agree & strongly agree
ICU patients with renal failure complicate decision-making when ordering antibiotics. 57.4 % Agree & strongly agree
Within physician service there is variation in VAP management depending on who is the VAP patient’s
attending physician.
56.8 % Agree & strongly agree
There is variation in VAP management between attending physicians and house staff in the ICU. 52.6 % Agree & strongly agree
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Antibiotic treatment guidelines have emerged as a po-
tentially effective means of avoiding unnecessary antibiotic
administration, increasing the effectiveness of prescribed
antibiotics, and reducing antimicrobial resistance as
well [33].
In our study, we attempted to understand the adoption
and uptake of a national VAP diagnosis and management
guideline [12]. Overall, we found that 55 % of participants
indicated that they were aware of the IDSA/ATS guideline.
The top ranked barriers to VAP management included: 1)
having multiple physician groups managing VAP, 2) vari-
ation in VAP management by differing ICU services, 3)
physicians and level of training, and 4) renal failure com-
plicating doses of antibiotics. Changes in renal clearance
following renal failure make it difficult to establish precise
antimicrobial dosing [34].
One of the top barriers to VAP management, having
multiple physician groups managing VAP may be more
likely to lead to poor patient outcomes particularly because
of the increased likelihood of communication errors in the
presence of multiple providers [35, 36].
Most respondents felt that nurse, pharmacist, and re-
spiratory therapy participation in rounds was beneficial
for VAP management. This finding further emphasizes the
need for multidisciplinary rounds which have been associ-
ated with improved patient outcomes such as reduced
mortality [37, 38] and reduced length of hospital stay [39].
Participants who were aware of the guideline also be-
lieved that they received effective training on management
and kept up to date on nosocomial infection literature.
However, they were less likely to believe that ICU respira-
tory therapists are capable of performing mini-BALs.
Compared to nurses, more pharmacists believed that
there was variation in VAP management. This is not sur-
prising because most of the variation in VAP manage-
ment occurs in antibiotic use and pharmacists have a
key role in that decision-making process. Awareness of
the guideline was also more likely to be associated with
Table 3 List of the top-ranked facilitators to VAP management
Facilitators Percent Response category
Pharmacist participation on ICU rounds is beneficial. 98.60 % Agree & strongly agree
Nurse participation on ICU rounds is beneficial. 98.00 % Agree & strongly agree
Respiratory therapist participation on ICU rounds is beneficial. 96.70 % Agree & strongly agree
I can readily access orders that are written for my ICU patients. 92.60 % Agree & strongly agree
Respiratory therapy services are readily available on my ICU. 92.30 % Fairly often & very often
Multidisciplinary management of patients occurs on my ICU. 91.90 % Agree & strongly agree
Nurses consistently participate on ICU patient rounds. 90.30 % Fairly often & very often
Physicians are receptive to pharmacist input in ICU patient care. 89.70 % Agree & strongly agree
Pharmacists on my ICU effectively monitor antibiotic use. 89.30 % Agree & strongly agree
Pharmacist participation in ICU patient management promotes appropriate antibiotic ordering. 89.00 % Agree & strongly agree
Pharmacists consistently participate on ICU patient rounds. 88.10 % Fairly often & very often
It is effective to have pharmacists help determine the appropriateness of ICU antibiotic de-escalation. 87.70 % Agree & strongly agree
I can readily access the information I want on my ICU patients in the EMR. 86.90 % Agree & strongly agree
Using VAP management guidelines helps me to manage VAP patients in the ICU. 86.70 % Agree & strongly agree
Pharmacy intervention in antibiotic ordering leads to effective ICU VAP management. 86.30 % Agree & strongly agree
Respiratory therapists consistently participate on ICU patient rounds. 83.20 % Fairly often & very often
I can appropriately manage ICU patients with VAP. 83.10 % Agree & strongly agree
VAP management guidelines interfere with my ability to manage my ICU patients. 82.30 % Occasionally & rarely
Table 4 Proportion of participants aware of the VAP management guideline per job category
Aware of IDSA/ATS guideline for VAP management Total
Yes No Missing
Physicians 8 10 0 18
Nurses 30 22 5 57
Respiratory therapists 22 17 10 49
Pharmacists 23 3 0 26
Total 83 52 15 150
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Table 5 Comparisons of professional groups’ perceptions and beliefs about various items related to VAP management
Theme Item Mean Rank P-Value
Communication between
providers
They would benefit by receiving clinical progress
reports feedback on VAP patients after they are
discharged from the ICU
Physicians vs. respiratory therapists, 43.1 vs 72.4 0.03
Physicians vs. pharmacists, 43.1 vs 85.2 0.02
Could more readily access information on ICU
patients from the EMR
Respiratory therapists vs. nurses,
= 62.8 vs 85.0
0.02
Difficulty in diagnosing VAP Being able to perform a bronchoscopy in the ICU
helps the physician to expeditiously diagnose VAP
Physicians aware of the guideline vs.
those not aware of it, 57.4 vs 68.7
0.05
Education related to VAP
and VAP management
Received effective training on VAP management Participants aware of the guideline vs. those
not aware of it, 56.7 vs 83.6
<.01
Kept up-to-date on nosocomial infection literature Participants aware of the guideline vs. those
not aware of it, 54.73 vs 85.81
<.001
Could appropriately manage ICU patients with VAP Participants aware of the guideline vs. those
not aware of it, 58.14 vs 71.35
0.01
Believe that they could easily interpret quantitative
culture results related to VAP (applicable to
physicians only)
Participants aware of the guideline vs. those
not aware of it, 55.92 vs 72.17
0.01
Believe that they could accurately diagnose ICU
patients with VAP (applicable to physicians only)
Participants aware of the guideline vs. those
not aware of it, 41.81 vs. 53.16
0.03
Kept up-to-date on nosocomial infection literature Pharmacists vs. nurses, 58.8 vs 83.9 <.01
Guideline awareness and use ICU VAP management order sets would facilitate
VAP management
Pharmacists vs. respiratory therapists, 51.5 vs 88.5 <.01
Physicians vs. respiratory therapists, 54.6 vs 88.5 <.01
VAP management guidelines interfere with their ability
to manage my ICU patients
Respiratory therapists vs. pharmacists, 44.0 vs 72.1 <.01
Management of the
condition
Having nurses float between ICUs interferes with
standardized VAP patient management
*Participants aware of the guideline vs. those
not aware of it, 70.1 vs 57.5
<.001
Physicians are receptive to respiratory therapist input
in ICU patient care
Physicians vs. respiratory therapists, 56.0 vs 87.9 <.01
Physicians are receptive to pharmacists’ input in
ICU patient care
Physicians vs. respiratory therapists, 52.3 vs 79.5 0.02
ICU patients with renal failure complicate decision-making
when ordering antibiotics
Physicians vs. pharmacists, 35.6 vs 70.7 <.01
Physicians vs. respiratory therapists, 35.6 vs 79.2 <.01
Nurses respiratory therapists, 56.1 vs 79.2 0.02
Provider responsibilities It is effective to have pharmacists help determine the
appropriateness of ICU antibiotic de-escalation
Participants aware of the guideline vs. those
not aware of it, 57.8 vs 73.2
<.001
Pharmacists vs. respiratory therapists, 49.9 vs 82.5 <.01
Attending physicians should be responsible for educating
house staff on VAP management guidelines
Participants aware of the guideline vs. those
not aware of it, 61.6 vs 74.5
0.04
Respiratory therapy does not respond promptly to mini-BAL
orders for ICU patients with suspected VAP
Participants aware of the guideline vs. those
not aware of it, 51.54 vs 41.3
0.05
Pharmacy intervention in antibiotic ordering leads to
effective ICU VAP management
Pharmacists vs. respiratory therapists, 50.5 vs 86.2, <.01
Nurses vs. respiratory therapists, 67.8 vs 86.2, 0.04
Multidisciplinary management of patients occurs on
their ICU
Pharmacists vs. respiratory therapists, 63.8 vs 88.1 0.04
Pharmacists on their ICU effectively monitor antibiotic use Pharmacists vs. respiratory therapists, 50.1 vs 82.9 <.01
Technology and its use Having an electronic medical record (EMR) reduces
the time necessary to diagnose VAP in the ICU
Physicians vs. nurses, 42.6 vs 75.9 0.04
Physicians vs. pharmacists, 42.6 vs 76.8 0.02
Use of clinically indicated tests ICU respiratory therapists are capable of performing
mini-BALs
*Participants aware of the guideline vs. those
not aware of it, 63.8
0.03
ICU respiratory therapists are capable of performing
mini-BALs
Respiratory therapists vs. pharmacists, 49.3 vs 84.2 <.01
More clinically useful specimens are collected when
mini-BALs are performed
Respiratory therapists vs. physicians, 49.3 vs 91.1 <.01
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belief that performing a bronchoscopy to diagnose VAP
would help with expeditious diagnosis of VAP.
Other studies have shown that implementing the
IDSA/ATS guideline by customizing it into center-specific
guidelines was associated with increased adherence to
guideline diagnostic criteria for nosocomial pneumonia
and guideline-concordant empiric antibiotics [40, 41]. Our
findings complement these existing studies by identifying
perceptions of the many different types of healthcare
workers (HCWs) in ICU settings.
Our study has limitations. Our survey was limited
to two institutions in Wisconsin and thus may limit
generalizability of our findings. We did not measure
guideline adherence or correlate it with outcomes. A
recent study found that guideline-adherent initial intra-
venous antibiotic therapy led to better patient outcomes
and was less expensive than non-guideline adherent ther-
apy [42]. However, other studies have shown that guideline
adherent care alone did not necessarily improve patient
outcomes such as the frequent need for mechanical venti-
lation and all-cause 30 day mortality [43, 44]. We did not
collect further data on the demographics of the respon-
dents to allow comparisons between attendings and
trainees for example. Knowledge of the guidelines might
be different between these categories. We had less phys-
ician participation than other types of HCWs. Finally, as
with any survey-based studies, we also cannot rule out the
possibility of variability in question interpretation [45, 46].
These limitations notwithstanding, our findings have
implications for antibiotic stewardship teams, clinicians,
and organizational leaders.
Conclusion
About half of the respondents reported that they were
aware of the IDSA/ATS guideline. Awareness of guidelines
was associated with a belief that respondents received ef-
fective training on management and kept up to date on
nosocomial infection literature. The top ranked barriers to
VAP management included having multiple physician
groups managing VAP, variation in VAP management by
differing ICU services, physicians and level of training and
renal failure complicating doses of antibiotics. Nurse,
pharmacist and respiratory therapy participation in rounds
was viewed as beneficial to VAP management by most re-
spondents. Future studies should rigorously examine the
impact of guideline adherence for VAP management to
clinical patient outcomes and assess process measures to
gauge degree and success of guideline implementation.
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